pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis.

[1]  S. W. Kim,et al.  Enhanced therapeutic efficacy of an adenovirus-PEI-bile-acid complex in tumors with low coxsackie and adenovirus receptor expression. , 2014, Biomaterials.

[2]  S. W. Kim,et al.  Utilizing adenovirus vectors for gene delivery in cancer , 2014, Expert opinion on drug delivery.

[3]  E. Kang,et al.  Therapeutic targeting of chitosan-PEG-folate-complexed oncolytic adenovirus for active and systemic cancer gene therapy. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[4]  S. W. Kim,et al.  Therapeutic efficacy of a systemically delivered oncolytic adenovirus - biodegradable polymer complex. , 2013, Biomaterials.

[5]  M. Ogris,et al.  Adenoviral vectors coated with PAMAM dendrimer conjugates allow CAR independent virus uptake and targeting to the EGF receptor. , 2013, Molecular pharmaceutics.

[6]  You Han Bae,et al.  Tumor heterogeneity and its implication for drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[7]  I. Choi,et al.  Adenovirus‐relaxin gene therapy for keloids: implication for reversing pathological fibrosis , 2011, The British journal of dermatology.

[8]  Gert Storm,et al.  Endosomal escape pathways for delivery of biologicals. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[9]  S. W. Kim,et al.  Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin. , 2011, Biomaterials.

[10]  S. Kawakami,et al.  Efficient gene transfection by histidine-modified chitosan through enhancement of endosomal escape. , 2010, Bioconjugate chemistry.

[11]  John D Lambris,et al.  An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood , 2010, Gene Therapy.

[12]  S. W. Kim,et al.  The effect of surface modification of adenovirus with an arginine-grafted bioreducible polymer on transduction efficiency and immunogenicity in cancer gene therapy. , 2010, Biomaterials.

[13]  J. Kopeček,et al.  HPMA copolymers: origins, early developments, present, and future. , 2010, Advanced drug delivery reviews.

[14]  L. Seymour,et al.  HPMA copolymers for masking and retargeting of therapeutic viruses. , 2010, Advanced drug delivery reviews.

[15]  Francesco Stellacci,et al.  Effect of surface properties on nanoparticle-cell interactions. , 2010, Small.

[16]  Joo‐Hang Kim,et al.  Novel cancer antiangiotherapy using the VEGF promoter-targeted artificial zinc-finger protein and oncolytic adenovirus. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  K. Ulbrich,et al.  Retargeting polymer‐coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer , 2008, The journal of gene medicine.

[18]  Joo‐Hang Kim,et al.  E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects. , 2007, Human gene therapy.

[19]  Y. Yoshioka,et al.  Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[20]  Y. Bae,et al.  Role of a Novel Excipient Poly(Ethylene Glycol)-b-Poly(L-Histidine) in Retention of Physical Stability of Insulin in Aqueous Solutions , 2007, Pharmaceutical Research.

[21]  Y. Bae,et al.  pH-induced micelle formation of poly(histidine-co-phenylalanine)-block-poly(ethylene glycol) in aqueous media. , 2005, Macromolecular bioscience.

[22]  Y. Tsutsumi,et al.  PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability , 2005, The journal of gene medicine.

[23]  S. Nakagawa,et al.  Design and synthesis of a peptide-PEG transporter tool for carrying adenovirus vector into cells. , 2005, Bioorganic & medicinal chemistry letters.

[24]  Yuan Zhang,et al.  Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  Erwin G. Van Meir,et al.  Cancer Therapy with a Replicating Oncolytic Adenovirus Targeting the Hypoxic Microenvironment of Tumors , 2004, Clinical Cancer Research.

[26]  D. Kirn,et al.  Replication-selective oncolytic adenoviruses. , 2004, Methods in molecular medicine.

[27]  You Han Bae,et al.  Polymeric micelle for tumor pH and folate-mediated targeting. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[28]  Hyun Joon Shin,et al.  Poly(L-histidine)-PEG block copolymer micelles and pH-induced destabilization. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[29]  S. Wadsworth,et al.  Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  H. Mizuguchi,et al.  Receptor-independent augmentation of adenovirus-mediated gene transfer with chitosan in vitro. , 2002, Biomaterials.

[31]  A. Hoque,et al.  Hydroxychloroquine enhances the endocrine secretion of adenovirus-directed growth hormone from rat submandibular glands in vivo. , 2001, Human gene therapy.

[32]  James M. Wilson,et al.  “Stealth” Adenoviruses Blunt Cell-Mediated and Humoral Immune Responses against the Virus and Allow for Significant Gene Expression upon Readministration in the Lung , 2001, Journal of Virology.

[33]  D. Kirn.  Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer , 2000, Oncogene.

[34]  R. Alemany,et al.  Blood clearance rates of adenovirus type 5 in mice. , 2000, The Journal of general virology.

[35]  B. Hann,et al.  Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015) , 2000, Nature Medicine.

[36]  D. Kirn,et al.  Replication-selective adenoviruses as oncolytic agents. , 2000, The Journal of clinical investigation.

[37]  M. Manns,et al.  Intravenous administration of recombinant adenoviruses causes thrombocytopenia, anemia and erythroblastosis in rabbits , 1999, The journal of gene medicine.

[38]  N. Sarvetnick,et al.  Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  G. Christofori,et al.  Polyethylenimine (PEI) is a simple, inexpensive and effective reagent for condensing and linking plasmid DNA to adenovirus for gene delivery , 1997, Gene Therapy.

[40]  B. Trapnell,et al.  Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy , 1996, Journal of virology.

[41]  P. V. van Diest,et al.  Heterogeneity and reproducibility of microvessel counts in breast cancer. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[42]  M. Green,et al.  Biochemical studies on adenovirus multiplication. II. Kinetics of nucleic acid and protein synthesis in suspension cultures. , 1961, Virology.

[43]  Maurice Green,et al.  Biochemical studies on adenovirus multiplication. 1. Stimulation of phosphorus incorporation into deoxyribonucleic acid and ribouncleic acid. , 1959, Virology.